We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.98B
AUM Growth
+$533M
Cap. Flow
+$206M
Cap. Flow %
10.36%
Top 10 Hldgs %
47.31%
Holding
123
New
37
Increased
37
Reduced
31
Closed
16

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$27.7M
2
GSK icon
GSK
GSK
+$26.1M
3
ABVX
Abivax
ABVX
+$25.2M
4
EXAS
Exact Sciences
EXAS
+$19.4M
5
DHR icon
Danaher
DHR
+$19.1M

Top Sells

Rank Stock Value
1
ZIMV
ZimVie
ZIMV
+$39.4M
2
NTRA icon
Natera
NTRA
+$38.6M
3
QURE icon
uniQure
QURE
+$31.4M
4
RVTY icon
Revvity
RVTY
+$22.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BKD icon
76
Brookdale Senior Living
BKD
$3.62B
$4.05M 0.2%
+374,929
New +$3.69M
NHC icon
77
National Healthcare
NHC
$3.53B
$3.92M 0.2%
+28,577
New +$3.69M
FTRE icon
78
Fortrea Holdings
FTRE
$1.85B
$3.87M 0.19%
224,139
+4,755
+2% +$58.7K
BVS icon
79
Bioventus
BVS
$799M
$3.51M 0.18%
471,257
+37,324
+9% +$268K
SPRY icon
80
ARS Pharmaceuticals
SPRY
$590M
$2.93M 0.15%
251,593
-724,918
-74% -$7.05M
AVR
81
Anteris Technologies
AVR
$791M
$2.5M 0.13%
500,000
– –
AMRN
82
Amarin Corp
AMRN
$284M
$2.4M 0.12%
172,188
+4,912
+3% +$81K
MRVI icon
83
Maravai LifeSciences
MRVI
$997M
$2.34M 0.12%
718,582
+427,909
+147% +$1.44M
EOLS icon
84
Evolus
EOLS
$394M
$2.29M 0.12%
344,104
-1,131,005
-77% -$7.66M
STRO icon
85
Sutro Biopharma
STRO
$379M
$2.24M 0.11%
193,571
-35,560
-16% -$337K
SRZN icon
86
Surrozen
SRZN
$229M
$2.15M 0.11%
95,286
+18,289
+24% +$296K
EHAB
87
DELISTED
Enhabit
EHAB
$2.01M 0.1%
+218,510
New +$1.89M
RAPP
88
Rapport Therapeutics
RAPP
$1.95B
$1.8M 0.09%
59,233
-84,332
-59% -$2.33M
IFRX icon
89
InflaRx
IFRX
$256M
$1.77M 0.09%
1,757,312
+26,677
+2% +$33.1K
BHVN icon
90
Biohaven
BHVN
$2.16B
$1.64M 0.08%
+145,431
New +$1.8M
CTNM
91
Contineum Therapeutics
CTNM
$526M
$1.57M 0.08%
137,493
+2,874
+2% +$32.8K
ALEC icon
92
Alector
ALEC
$164M
$1.57M 0.08%
1,006,163
-482,562
-32% -$856K
NVCR icon
93
NovoCure
NVCR
$2.04B
$1.56M 0.08%
+120,978
New +$1.55M
QURE icon
94
uniQure
QURE
$2.68B
$1.5M 0.08%
62,820
-814,553
-93% -$31.4M
PASG icon
95
Passage Bio
PASG
$15.9M
$1.49M 0.08%
+126,230
New +$1.09M
BCYC
96
Bicycle Therapeutics
BCYC
$270M
$1.27M 0.06%
178,915
-15,525
-8% -$114K
NVAX icon
97
Novavax
NVAX
$1.23B
$1.22M 0.06%
181,220
-61,964
-25% -$467K
PLRX icon
98
Pliant Therapeutics
PLRX
$67.5M
$1.03M 0.05%
842,023
+17,429
+2% +$26.2K
SVRA icon
99
Savara
SVRA
$1.13B
$1.03M 0.05%
+170,195
New +$834K
EHTH icon
100
eHealth
EHTH
$42.5M
$1.02M 0.05%
222,570
+94,248
+73% +$415K
1 2 3
4
5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Eversept Partners held 123 positions worth $1.98B, up 37% from $1.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners deployed $206M of net new capital in Q4 2025, opening 37 new positions and adding to 37 existing holdings. Its largest new stake was Exact Sciences: 241,678 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $38.6M trimmed.

  • Eversept Partners's largest Q4 2025 buy was Exact Sciences: 241,678 shares worth $24.5M.
  • Eversept Partners added most to Avantor in Q4 2025, an estimated $27.7M increase.
  • Eversept Partners's biggest Q4 2025 reduction was Natera, cutting an estimated $38.6M.
  • Eversept Partners fully exited ZimVie in Q4 2025, selling an estimated $39.4M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.98B portfolio in Q4 2025.
  • Eversept Partners opened 37 new positions and closed 16 in Q4 2025.
  • Eversept Partners's portfolio value rose 37% quarter-over-quarter to $1.98B.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.